143 related articles for article (PubMed ID: 29108288)
1. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.
Palandri F; Palumbo GA; Bonifacio M; Tiribelli M; Benevolo G; Martino B; Abruzzese E; D'Adda M; Polverelli N; Bergamaschi M; Tieghi A; Cavazzini F; Ibatici A; Crugnola M; Bosi C; Latagliata R; Di Veroli A; Scaffidi L; de Marchi F; Cerqui E; Anaclerico B; De Matteis G; Spinsanti M; Sabattini E; Catani L; Aversa F; Di Raimondo F; Vitolo U; Lemoli RM; Fanin R; Merli F; Russo D; Cuneo A; Bacchi Reggiani ML; Cavo M; Vianelli N; Breccia M
Oncotarget; 2017 Oct; 8(45):79073-79086. PubMed ID: 29108288
[TBL] [Abstract][Full Text] [Related]
2. Light and shade of ruxolitinib: positive role of early treatment with ruxolitinib and ruxolitinib withdrawal syndrome in patients with myelofibrosis.
Baek DW; Cho HJ; Lee JM; Kim J; Moon JH; Sohn SK
Expert Rev Hematol; 2022 Jul; 15(7):573-581. PubMed ID: 35679520
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
Palandri F; Tiribelli M; Breccia M; Bartoletti D; Elli EM; Benevolo G; Martino B; Cavazzini F; Tieghi A; Iurlo A; Abruzzese E; Pugliese N; Binotto G; Caocci G; Auteri G; Cattaneo D; Trawinska MM; Stella R; Scaffidi L; Polverelli N; Micucci G; Masselli E; Crugnola M; Bosi C; Heidel FH; Latagliata R; Pane F; Cuneo A; Krampera M; Semenzato G; Lemoli RM; Cavo M; Vianelli N; Bonifacio M; Palumbo GA
Cancer; 2021 Aug; 127(15):2657-2665. PubMed ID: 33794557
[TBL] [Abstract][Full Text] [Related]
4. [Ruxolitinib combined with prednisone, thalidomide and danazol for treatment of myelofibrosis: a pilot study].
Xu ZF; Qin TJ; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Li B; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2019 Jan; 40(1):24-28. PubMed ID: 30704224
[No Abstract] [Full Text] [Related]
5. Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Palandri F; Breccia M; Mazzoni C; Auteri G; Elli EM; Trawinska MM; Polverelli N; Tiribelli M; Benevolo G; Iurlo A; Tieghi A; Heidel FH; Caocci G; Beggiato E; Binotto G; Cavazzini F; Miglino M; Bosi C; Crugnola M; Bocchia M; Martino B; Pugliese N; Biondo M; Venturi M; Scaffidi L; Isidori A; Cattaneo D; Krampera M; Pane F; Cilloni D; Semenzato G; Lemoli RM; Cuneo A; Abruzzese E; Bartoletti D; Paglia S; Vianelli N; Cavo M; Bonifacio M; Palumbo GA
Cancer; 2023 Jun; 129(11):1704-1713. PubMed ID: 36932983
[TBL] [Abstract][Full Text] [Related]
6. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.
Verstovsek S; Gotlib J; Gupta V; Atallah E; Mascarenhas J; Quintas-Cardama A; Sun W; Sarlis NJ; Sandor V; Levy RS; Kantarjian HM; Mesa RA
Onco Targets Ther; 2013; 7():13-21. PubMed ID: 24368888
[TBL] [Abstract][Full Text] [Related]
7. Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.
Palandri F; Bartoletti D; Iurlo A; Bonifacio M; Abruzzese E; Caocci G; Elli EM; Auteri G; Tiribelli M; Polverelli N; Miglino M; Heidel FH; Tieghi A; Benevolo G; Beggiato E; Fava C; Cavazzini F; Pugliese N; Binotto G; Bosi C; Martino B; Crugnola M; Ottaviani E; Micucci G; Trawinska MM; Cuneo A; Bocchia M; Krampera M; Pane F; Lemoli RM; Cilloni D; Vianelli N; Cavo M; Palumbo GA; Breccia M
Cancer; 2022 Jul; 128(13):2449-2454. PubMed ID: 35363892
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.
Polverelli N; Palumbo GA; Binotto G; Abruzzese E; Benevolo G; Bergamaschi M; Tieghi A; Bonifacio M; Breccia M; Catani L; Tiribelli M; D'Adda M; Sgherza N; Isidori A; Cavazzini F; Martino B; Latagliata R; Crugnola M; Heidel F; Bosi C; Ibatici A; Soci F; Penna D; Scaffidi L; Aversa F; Lemoli RM; Vitolo U; Cuneo A; Russo D; Cavo M; Vianelli N; Palandri F
Hematol Oncol; 2018 Apr; ():. PubMed ID: 29624703
[TBL] [Abstract][Full Text] [Related]
9. Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years.
Masarova L; Bose P; Pemmaraju N; Zhou L; Pierce S; Estrov Z; Kantarjian H; Verstovsek S
Acta Haematol; 2023; 146(6):522-529. PubMed ID: 37699357
[TBL] [Abstract][Full Text] [Related]
10. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis.
Maffioli M; Mora B; Ball S; Iurlo A; Elli EM; Finazzi MC; Polverelli N; Rumi E; Caramella M; Carraro MC; D'Adda M; Molteni A; Sissa C; Lunghi F; Vismara A; Ubezio M; Guidetti A; Caberlon S; Anghilieri M; Komrokji R; Cattaneo D; Della Porta MG; Giorgino T; Bertù L; Brociner M; Kuykendall A; Passamonti F
Blood Adv; 2022 Mar; 6(6):1855-1864. PubMed ID: 35130339
[TBL] [Abstract][Full Text] [Related]
11. Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib.
Cattaneo D; Galli N; Bucelli C; Fidanza CA; Bellani V; Artuso S; Bianchi P; Consonni D; Passamonti F; Iurlo A
Ann Hematol; 2024 Jun; ():. PubMed ID: 38864904
[TBL] [Abstract][Full Text] [Related]
12. A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis.
Palandri F; Palumbo GA; Bonifacio M; Elli EM; Tiribelli M; Auteri G; Trawinska MM; Polverelli N; Benevolo G; Tieghi A; Cavalca F; Caocci G; Beggiato E; Binotto G; Cavazzini F; Miglino M; Bosi C; Crugnola M; Bocchia M; Martino B; Pugliese N; Venturi M; Isidori A; Cattaneo D; Krampera M; Pane F; Cilloni D; Semenzato G; Lemoli RM; Cuneo A; Abruzzese E; Branzanti F; Vianelli N; Cavo M; Heidel F; Iurlo A; Breccia M
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894394
[TBL] [Abstract][Full Text] [Related]
13. AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib.
Duminuco A; Mosquera-Orgueira A; Nardo A; Di Raimondo F; Palumbo GA
Cancer Rep (Hoboken); 2023 Oct; 6(10):e1881. PubMed ID: 37553891
[TBL] [Abstract][Full Text] [Related]
14. Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review.
Peng Y; Meng L; Hu X; Han Z; Hong Z
Infect Drug Resist; 2020; 13():3309-3316. PubMed ID: 33061478
[TBL] [Abstract][Full Text] [Related]
15. Incidence of blast phase in myelofibrosis according to anemia severity.
Mora B; Maffioli M; Rumi E; Guglielmelli P; Caramella M; Kuykendall A; Palandri F; Iurlo A; De Stefano V; Kiladjian JJ; Elli EM; Polverelli N; Gotlib J; Albano F; Silver RT; Benevolo G; Ross DM; Devos T; Borsani O; Barbui T; Porta MGD; Bertù L; Komrokji R; Vannucchi AM; Passamonti F
EJHaem; 2023 Aug; 4(3):679-689. PubMed ID: 37601878
[TBL] [Abstract][Full Text] [Related]
16. Trend of circulating CD34
Iurlo A; Galli N; Bucelli C; Artuso S; Consonni D; Cattaneo D
Br J Haematol; 2023 Feb; 200(3):315-322. PubMed ID: 36266779
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.
Polverelli N; Breccia M; Benevolo G; Martino B; Tieghi A; Latagliata R; Sabattini E; Riminucci M; Godio L; Catani L; Nicolosi M; Perricone M; Sollazzo D; Colafigli G; Campana A; Merli F; Vitolo U; Alimena G; Martinelli G; Lewis RE; Vianelli N; Cavo M; Palandri F
Am J Hematol; 2017 Jan; 92(1):37-41. PubMed ID: 27701770
[TBL] [Abstract][Full Text] [Related]
18. Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.
Davis KL; Côté I; Kaye JA; Mendelson E; Gao H; Perez Ronco J
Adv Hematol; 2015; 2015():848473. PubMed ID: 26635878
[TBL] [Abstract][Full Text] [Related]
19. Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma.
Ishibashi N; Maebayashi T; Aizawa T; Sakaguchi M; Abe O; Saito T; Tanaka Y
Hematology; 2015 May; 20(4):203-7. PubMed ID: 25131182
[TBL] [Abstract][Full Text] [Related]
20. Clinical Efficacy of Ruxolitinib in Patients with Myelofibrosis: A Nationwide Population-Based Study in Korea.
Lee BH; Moon H; Chae JE; Kang KW; Kim BS; Lee J; Park Y
J Clin Med; 2021 Oct; 10(20):. PubMed ID: 34682897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
